Table 1.

Clinical features of B-cell lymphoma patients

Patient	Disease	State at enrollment	Tumor features	Previous treatment
CLL1	Chronic lymphocytic leukemia (CLL)	Relapsed	Stage IV Rai. High-risk features, including unmutated IGHV gene status, complex karyotype, TP53 disruption (both deletion and mutation).	Ibrutinib failure.
CLL2	CLL	Relapsed	Stage IV Rai. Unfavorable prognostic markers including complex karyotype and TP53 mutation.	Several lines of treament: fludarabine-cyclophosphamde-rituximab, twice, rituximab single agent, BR (bendamustine-rituximab), ibrutinib, venetoclax.
CLL3	CLL	Naïve	Stage II Rai. Favorable prognostic variable, including mutated status of IGHV gene, normal FISH and karyotype, absence of TP53 mutation.	–
CLL4	CLL	Naïve	Stage II Rai. Favorable markers (mutated conformation of IGHV, 13q14 deletion and absence of both TP53 deletion or mutation).	–
MCL1	Mantle cell lymphoma (MCL)	Naïve	Stage IV. Absence of TP53 mutation	–
MCL2	MCL	Relapsed	Stage IVB blastoid variant, t(11;14) +.	Three alternating cycles of R-CHOP21 with R-DHAOx (total cycles n=6) and autologous stem cell transplantation.Ibrutinib failure.
SMZL1	Splenic marginal zone lymphoma (SMZL)	Naïve	Stage IV	–
SMZL2	SMZL	Relapsed	Stage IVA, extranodal localization.	Splenectomy, BR, ibrutinib and venetoclax.
B-ALL1	Early B cell precursor acute lymphoid leukemia (B-ALL)	Relapsed	High-risk according to 2016 WHO classification: t(t;11) (4q21;11q23).	Prephase: cyclophosphamide and prednisone. I cycle: idarubicin, dexamethasone, vincristine e peg- asparaginase. II cycle: idarubicin, cyclophosphamide, cytarabine, 6-mercaptopurine, dexamethasone. Intrathecal therapy with methotrexate, cytarabine and dexamethasone. III cycle: methotrexate and cytarabine. At first relapse received dexamethasone for 2 days and vincristine for 1 day as debulking, followed by blinatumomab according to conventional doses and schedule. Blood sample was taken at the second relapse.

IGHV, immunoglobulin heavy chain variable.